Abiopharma

🔍 Peterson James J (Director)

Company: MOBIX LABS, INC (MOBX)

Report Date: 2026-02-25

Detailed Transactions and Holdings:

• Acquired 14,805 shares of Class A Common Stock (Direct)
  Date: 2026-02-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 320,462.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 5,000 shares of Class A Common Stock (Direct)
  Date: 2026-03-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 325,462.00 | transaction_form_type: 4
• Holds 2,000 shares of Option (Right to Buy) at $41.8 per share (Derivative)
  Date: 2026-02-25 | Code: H | Expires: 2030-08-10 | shares_owned_after: 2,000.00 | Footnotes: F3
• Holds 13,341 shares of Option (Right to Buy) at $68.4 per share (Derivative)
  Date: 2026-02-25 | Code: H | Expires: 2032-04-04 | shares_owned_after: 13,341.00 | Footnotes: F3
• Holds 144,927 shares of Class B Common Stock (Derivative)
  Date: 2026-02-25 | Code: H | shares_owned_after: 144,927.00 | Footnotes: F4, F4, F4

Footnotes:

• F1: These Restricted Stock Units ("RSUs") were granted to the Reporting Person on February 25, 2026 and vested on April 1, 2026.
• F2: The number of shares beneficially owned by the Reporting Person has been adjusted to account for rounding as a result of a 1-for-10 reverse stock split effected by the Issuer on April 6, 2026.
• F3: These options are fully vested and exercisable.
• F4: The shares of Class B Common Stock are convertible into shares of Class A Common Stock at the option of the Reporting Person, and will be automatically converted upon (i) a transfer by the Reporting Person (other than a permitted transfer) or (ii) the first trading day after the seventh anniversary date of the Closing Date (December 21, 2023).
• REMARKS: The share amounts reported in Tables I and II and the exercise prices of the options in Table II have been adjusted to reflect a 1-for-10 reverse stock split effected by the Issuer on April 6, 2026.